4D Molecular Therapeutics (FDMT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$1.02
- Surprise
- —
- Revenue (period 2026-06-30)
- $3.8M
- Score today
- 5.3/10
Revenue source: xbrl.
Where TrendMatrix's rating stands now
TrendMatrix currently rates FDMT Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-10.
What argues against it
- Quality below floor (2.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.43
- Price target
- $25.32
- Stop
- $14.72
- Upside to target
- +64.1%
- Reward-to-risk
- 4.0:1
Risk check: RSI 86 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
FDMT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $874.5M
- P/E (fwd)
- -3.9
- 52-week range
- $5.97–$16.93
- Off 52-week high
- 8.9%
- RSI (14)
- 86
- Volume vs avg
- 0.97×
- Score today
- 5.3/10